cerca CERCA
Sabato 26 Novembre 2022
Aggiornato: 09:38
Temi caldi

Shanghai Jemincare Pharmaceutical Co.

comunicato stampa

Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader

SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Jemincare, a leading pharmaceutical company from China, announced today that it and its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., have entered into an exclusive worldwide license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) and Genentech, a member of the Roche Group, for the development and commercialization of its androgen receptor degrader, JMKX002992.

ora in
Prima pagina
in Evidenza